

2022 Cardiology Pharmacy Specialty Recertification Literature Study:

Module 1A: Updates in Heart Failure

Articles and Learning Objectives

Cardiology Pharmacy Literature Study Module 1A: Updates in Heart Failure

ACPE #: 0204-9999-22-958-H01-P

Contact Hours: 4.5

Activity Type: Application-based

This module focuses on guideline-directed medical therapy, diuretic resistance and updates in heart failure with preserved ejection fraction.

Carnicelli AP, Lippmann SJ, Greene SJ et al. Sacubitril/valsartan initiation and postdischarge adherence among patients hospitalized for heart failure. *J Card Fail.* 2021; 27:826-36.

Learning Objectives:

- Describe the study by Carnicelli and colleagues of angiotensin receptor neprilysin inhibitor (ARNI) therapy in patients hospitalized for heart failure with reduced ejection fraction (HFrEF).
- Develop recommendations for the timing of sacubitril/valsartan initiation in patients hospitalized for heart failure with reduced ejection fraction (HFrEF).

Bhatt DL, Szarek M, Steg PG et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. *N Engl J Med.* 2021; 384:117-28.

Learning Objectives:

- Describe the Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) trial.
- Develop recommendations for the use of sotagliflozin in patients with type 2 diabetes mellitus and worsening heart failure.

Anker SD, Butler J, Filippatos G et al. Empagliflozin in heart failure with a preserved ejection fraction. *N Engl J Med.* 2021; 385:1451-61.

Learning Objectives:

- Describe the Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction (EMPEROR-Preserved),

- Develop recommendations for the use of empagliflozin in patients with chronic heart failure with preserved ejection fraction (HFpEF).

Palau P, Seller J, Domínguez E et al. Effect of β -blocker withdrawal on functional capacity in heart failure and preserved ejection fraction. *J Am Coll Cardiol.* 2021; 78:2042-56.

Learning Objectives:

- Describe the PRESERVE-HR study by Palau and colleagues of β -blocker withdrawal in patients with heart failure and preserved ejection fraction (HFpEF) and chronotropic incompetence.
- Develop recommendations for the use of β -blockers in patients with heart failure and preserved ejection fraction (HFpEF) and chronotropic incompetence.

Rao VS, Ivey-Miranda JB, Cox ZL, et al. Natriuretic equation to predict loop diuretic response in patients with heart failure. *J Am Coll Cardiol.* 2021; 77:695-708.

Learning Objectives:

- Describe the study by Rao and colleagues of the use of a natriuretic response prediction equation (NRPE) to guide intravenous (IV) loop diuretic therapy in patients with acute decompensated heart failure (ADHF).
- Develop recommendations for the use of predictive tools to guide intravenous (IV) loop diuretic therapy in patients with acute decompensated heart failure (ADHF).

Felker GM, Ellison DH, Mullens W et al. Diuretic therapy for patient with heart failure—JACC state-of-the-art review. *J Am Coll Cardiol.* 2020; 75:1178-95.

Learning Objectives:

- Describe renal physiology and response to diuretics, the pharmacology and pharmacodynamics of diuretics, mechanisms and strategies for overcoming diuretic resistance, and loop diuretic use in patients with acute or chronic heart failure.
- Develop recommendations for the use of diuretic therapy in patients with heart failure.